Xbrane Biopharma AB (DE:7XB0)
FRANKFURT:7XB0
Want to see DE:7XB0 full AI Analyst Report?
7XB0 Stock Chart & Stats
€0.69
>-€0.01(-1.14%)
―
--
Day’s Range― - ―
52-Week Range€0.45 - €3.78
Previous CloseN/A
VolumeN/A
Average Volume (3M)8.00
Market Cap
€15.84M
Enterprise Value€72.53M
Total Cash (Recent Filing)€86.59M
Total Debt (Recent Filing)€58.31M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
May 05, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding20,605,349
10 Day Avg. Volume25
30 Day Avg. Volume8
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)27.69
Price to Sales (P/S)101.88
P/FCF Ratio-61.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.39
Revenue Forecast (FY)€17.46M
Bulls Say, Bears Say
Bulls Say
Strengthened 2025 Balance SheetMaterial deleveraging and a larger equity base in 2025 reduce near-term refinancing pressure and improve financial flexibility. A stronger capital structure supports R&D progress and partnership talks, lowering execution risk while the company advances biosimilar programs.
Clinical And Manufacturing CapabilitiesOwning biologics development and manufacturing expertise is a durable competitive asset in biosimilars. It shortens tech transfer, lowers partner onboarding friction, and supports contract services or licensing revenue that can persist beyond single programs.
Partnership/out‑licensing Business ModelA business model centered on partnerships and milestone-driven payments lowers capital intensity and transfers commercialization risk to partners. This model provides recurring dealflow potential and aligns incentives, supporting steadier long-term funding sources if deal execution continues.
Bears Say
Deep, Persistent Cash BurnSustained negative operating and free cash flow forces continuous external financing or dilutive equity raises. Over a multi‑quarter horizon, this constrains strategic optionality, increases dilution risk, and makes timely funding of development milestones contingent on capital markets or partners.
Core Operations UnprofitableChronic operating losses indicate the business lacks self-sustaining profitability from core activities. Reliance on non-operating gains for reported net income is not durable; absent structural margin improvement, the company will remain dependent on external financing or successful licensing outcomes.
Revenue Volatility And Recent DeclinesInstability in revenue undermines predictability of milestone and royalty receipts, complicating multi-quarter planning and partner negotiations. Continued top-line volatility elevates execution risk for R&D programs and weakens the company's ability to steadily reduce funding reliance.
Xbrane Biopharma AB News
7XB0 FAQ
What was Xbrane Biopharma AB’s price range in the past 12 months?
Xbrane Biopharma AB lowest stock price was €0.45 and its highest was €3.77 in the past 12 months.
What is Xbrane Biopharma AB’s market cap?
Xbrane Biopharma AB’s market cap is €15.84M.
When is Xbrane Biopharma AB’s upcoming earnings report date?
Xbrane Biopharma AB’s upcoming earnings report date is May 05, 2026 which is in 18 days.
How were Xbrane Biopharma AB’s earnings last quarter?
Xbrane Biopharma AB released its earnings results on Feb 20, 2026. The company reported -€0.118 earnings per share for the quarter, beating the consensus estimate of -€0.137 by €0.019.
Is Xbrane Biopharma AB overvalued?
According to Wall Street analysts Xbrane Biopharma AB’s price is currently Undervalued.
Does Xbrane Biopharma AB pay dividends?
Xbrane Biopharma AB does not currently pay dividends.
What is Xbrane Biopharma AB’s EPS estimate?
Xbrane Biopharma AB’s EPS estimate is -0.05.
How many shares outstanding does Xbrane Biopharma AB have?
Xbrane Biopharma AB has 20,605,349 shares outstanding.
What happened to Xbrane Biopharma AB’s price movement after its last earnings report?
Xbrane Biopharma AB reported an EPS of -€0.118 in its last earnings report, beating expectations of -€0.137. Following the earnings report the stock price went down -2.818%.
Which hedge fund is a major shareholder of Xbrane Biopharma AB?
Currently, no hedge funds are holding shares in DE:7XB0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xbrane Biopharma AB
Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.
Technical Analysis
Options Prices
Currently, No data available
---